Elagolix – GnRH Antagonist

GnRH is a peptide that stimulates the secretion of the pituitary hormones that are responsible for sex steroid production and normal reproductive function. Elagolix is a novel, orally administered gonadotropin-releasing hormone (GnRH) antagonist. Elagolix is believed to have its effect by altering the level of pituitary GnRH suppression and, as a result, titrating circulating hormone levels. By this method, it is believed that elagolix may provide relief from the pain associated with conditions such endometriosis uterine fibroids and polycystic ovary syndrome.

ELAGOLIX DEVELOPMENT: ABBVIE COLLABORATION

In June 2010, Neurocrine Biosciences entered into an exclusive worldwide collaboration with AbbVie (formerly Abbott) to develop and commercialize elagolix for women’s health. Under the terms of the agreement, AbbVie is responsible for future development and commercialization.

In 2018, AbbVie received U.S. FDA approval for ORILISSA® (elagolix) to treat pain associated with endometriosis. In 2020, AbbVie received U.S. FDA approval for ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) to manage heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Under the collaboration, elagolix is also being investigated for the treatment of polycystic ovary syndrome. AbbVie is responsible for all development, marketing and commercialization costs and Neurocrine Biosciences is entitled to a royalty on worldwide sales of ORILISSA, ORIAHNN and other products containing elagolix.